New drug targets for Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) persists as a major global infectious disease, causing significant mortality worldwide.
• Despite advances in understanding Mycobacterium tuberculosis biology and available genomic tools, no new drugs have emerged in 30 years.
• Factors like HIV co-infection, drug resistance, and variable vaccine efficacy contribute to TB's persistent threat.

Purpose of the Study:

• To identify and discuss potential new drug targets for combating Mycobacterium tuberculosis.
• To highlight the need for novel therapeutic strategies due to the lack of new drug development.
• To explore the exploitation of host cell signaling pathways as a novel approach against TB.

Main Methods:

• Review of current literature on Mycobacterium tuberculosis biology and drug discovery.
• Analysis of potential drug targets based on essential bacterial processes (metabolism, persistence, transcription, cell wall synthesis, virulence).
• Investigation of host-pathogen interactions, specifically reversible phosphorylation, as a potential therapeutic avenue.

Main Results:

• The complete genome sequence of M. tuberculosis provides a rational basis for identifying new drug targets.
• Gene products involved in essential mycobacterial functions are promising targets.
• Host cell signaling pathways, particularly protein phosphorylation, offer new perspectives for drug development.

Conclusions:

• Urgent need for new drugs to combat tuberculosis due to treatment challenges and lack of innovation.
• Potential drug targets lie within essential mycobacterial pathways and host-pathogen interactions.
• Exploring host protein modification by mycobacteria presents a promising strategy for novel anti-TB therapies.